Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciBase Holding ABOSTO:SCIB +1.45%61 3-Year EBITDA Growth Rate is 25.60% as of Mar. 2026, which is 11% above its 10-year median of 23.15. GuruFocus rates OSTO:SCIB with a GF Score™ of 61/100 and a GF Value™ of kr21.71 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 692 Medical Devices & Instruments companies, SciBase Holding AB ranks better than 72.54% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 25.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 24.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of SciBase Holding AB was 35.70% per year. The lowest was 4.30% per year. And the median was 23.15% per year.
SciBase Holding AB (OSTO:SCIB) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
SciBase Holding AB 3-Year EBITDA Growth Rate Related Terms
OSTO:SCIB vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, SciBase Holding AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciBase Holding AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SciBase Holding AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where SciBase Holding AB's 3-Year EBITDA Growth Rate falls into.
SciBase Holding AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 25.60% mean?
SciBase Holding AB (OSTO:SCIB) has a 3-Year EBITDA Growth Rate of 25.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SciBase Holding AB and its competitors. This is 11% above median its historical median of 23.15. Over the past decade, SciBase Holding AB's 3-Year EBITDA Growth Rate has ranged from 4.30 to 35.70. According to the industry distribution chart, SciBase Holding AB ranks #190 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 27.5%.
Is SciBase Holding AB's 3-Year EBITDA Growth Rate too high?
SciBase Holding AB's current 3-Year EBITDA Growth Rate of 25.60% is 11% above median its 10-year median of 23.15. Over the past 10 years, this metric has ranged from a low of 4.30 to a high of 35.70. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. SciBase Holding AB's value of 25.60% is 212.2% above this industry median. Based on the distribution chart, SciBase Holding AB ranks #190 out of 692 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SciBase Holding AB has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciBase Holding AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SciBase Holding AB ranks #190 out of 692 companies for 3-Year EBITDA Growth Rate. This puts SciBase Holding AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. SciBase Holding AB's value of 25.60% is 212.2% above this benchmark. Historically, SciBase Holding AB's own 3-Year EBITDA Growth Rate has ranged from 4.30 to 35.70 over the past decade. While the company's 10-year median is 23.15 vs. the industry median of 8.20, SciBase Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SciBase Holding AB's current 3-Year EBITDA Growth Rate of 25.60% is 212.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SciBase Holding AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SciBase Holding AB's current 3-Year EBITDA Growth Rate is 25.60%, which is 11% above median its own 10-year median of 23.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciBase Holding AB stock overvalued right now?
Based on GuruFocus' analysis, SciBase Holding AB (OSTO:SCIB) is currently considered Modestly Overvalued. The stock's GF Value™ is kr21.71, compared to a current price of kr27.90 — trading 28.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 25.60%, which is 11% above median its 10-year median of 23.15 and 212.2% above the Medical Devices & Instruments industry median of 8.20. SciBase Holding AB's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For SciBase Holding AB (OSTO:SCIB), the current 3-Year EBITDA Growth Rate is 25.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?
Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued.
The current stock price of kr27.90 is trading 28.5% above its estimated GF Value™ of kr21.71.
GuruFocus considers SciBase Holding AB to be Modestly Overvalued.
Key valuation signals for OSTO:SCIB:
3-Year EBITDA Growth Rate: 25.60% (11% above median its 10-year median of 23.15)
GF Value™: kr21.71 vs. price of kr27.90 (28.5% above fair value)
Industry Position: 212.2% above the Medical Devices & Instruments median (#190 of 692)
No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
61GF Score
Get the complete analysis for OSTO:SCIB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SCIB has been successfully added to your 
